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1. Introduction 
The increased use of animals in fundamental and applied research due to the remarkable 
drug development in the 20th century has been an important matter of concern for people at 
large, but also for the scientific community. This led Russel and Burch to examine the 
decisions which could meliorate this situation, and they proposed, in 1959, the principle of 
the 3Rs (Reduce, Refine, and Replace) nowadays largely admitted as an ethical and 
incontrovertible principle (Russell & Bursch 1959). Alternatives to animal experiments 
(Scheme 1) then knew a fantastic boom with the permanent objective of a high scientific 
quality in order to prevent, treat and cure human illness. 
Reaching the equilibrium between in vitro and in vivo models, observing the 3Rs rules, is 
very difficult. Effectively, in vitro systems allow an excellent control of all parameters of the 
experiments, and then, good quantifications. More the models are simple, more they are 
easy to handle, but more they also are dedifferentiated and keep away from the in vivo 
situation. 
 
 
Scheme 1. In vitro systems as alternatives to the use of animals. 
Within the framework of this book, the question becomes now: how the 3Rs could be the 
best way to phase out animal experiments when considering breast cancer? We try to bring 
some response elements in this chapter, emphasising the in vitro models the most useful and 
the most frequently used. But we also show that no model is perfect and sufficient by itself, 
and that pure in vitro models also need assistance of in vivo ones. 
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2. Models for investigation on breast cancer 
2.1 Established breast cancer cell lines 
2.1.1 The different cell lines and their main properties 
Significant amounts of data on breast cancer have been collected over the past 40 years, 
thanks to the use of established cell lines. The first breast cancer cell lines (BCCL) have been 
established in the sixties-seventies and very few new cell lines have been developed since. 
Only a hundred of BCCL are currently available and three of them have been extensively 
studied and represent now nearly 80% of the 35 000 publications mentioning breast cancer 
cell lines (Lacroix & Leclercq 2004).  
Most of the cell lines were created from cells derived from metastasis or from pleural 
effusion. Pleural effusions contain large amounts of well isolated tumour cells and few 
contaminating cells such as fibroblasts, thus making their recovery and growing easier than 
those of cells directly derived from primary tumours or metastasis. Moreover, metastatic 
cells are highly dedifferentiated cells, which allow their cultivation more successfully than 
the primary tumour cells. 
The three more used BCCL (MCF-7, MDA-MB-231 and T47D) are issued from pleural 
effusion of an invasive ductal carcinoma (Soule et al. 1973; Cailleau et al. 1974; Keydar et al. 
1979), and they mainly differ by their oestrogen receptor (ER) and progesterone receptor 
(PgR) status: MCF-7 and T47D are ER+ PgR+ while MDA-MB-231 is ER- PgR-. Among these 
three cell lines, MCF-7 was the most often used during the last ten years: it has been cited in 
53% of all the scientific papers mentioning BCCL, while MDA-MB-231 and T47D were 
respectively cited in about 18% and 7% of these articles (calculation made on the basis of a 
Medline-based survey in March 2011). 
The use of these lines has many technical advantages.  
 The complete control of environmental conditions and standardised culture conditions 
ensures the reproducibility of results between experiments and laboratories.  
 Maintaining cells in culture is much less costly than working on animal models. Besides 
the fact that some animal models are expensive by themselves, the care of animals and 
the staff necessary to a good work in an animal house are the main drain of resources. 
Conversely, the medium and the staff time required to growth cells are cheaper, thus 
allowing the widespread use of BCCL. 
  Cryopreservation enables long-term conservation of the same strain and can 
theoretically permit the use of these cell lines indefinitely.  
These advantages have allowed to gather essential data for the study of breast cancer in the 
last 40 years, making these cell lines reference models in the field with the establishment of a 
complete genetic and proteinic profile.  
2.1.2 The main drawbacks of these models 
- Stability/instability 
In practice, these strains, although cryopreserved, undergo dedifferentiation resulting from 
multiple subcultures, and leading to the lost of special characteristics. Moreover, differences 
in the culturing practices (medium composition, time between subcultures, subculturing 
technique, etc.), can explain some divergences observed for a same strain in different 
laboratories. 
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- Simplicity 
The relevance of cellular models is controversial since their over-simplicity implies 
difficulties in extrapolating results from the cell line to the tumour in humans and thus 
raises the question of their representativeness. 
Indeed, cell lines are homogeneous, theoretically consisting only of a single cell type (pure 
and clonal) due to the way they are established: 
- The dislocation of tumours is followed by isolation of cells, in order to obtain the 
most stable culture during subcultures.  
- The culture conditions eliminate some types of cells present in the original tumour, 
unable to grow on a synthetic surface, or whose rate of development is much lower 
than the one of the surviving cells.  
- Cells in culture do not undergo the influence of nervous and hormonal regulatory 
systems active in vivo.  
These particularities reduce the similarity with the primary tumour. 
- Limited representativeness 
The hundred of available cell lines do not cover all of the tumour features found in 
patients. Furthermore, the proportions of some characteristics are sometimes reversed, 
such as the ER and PgR status which is very different in cell lines, compared to that found 
in the patient population (Lacroix & Leclercq 2004). These dissimilarities can be explained 
by the fact that most lines are derived from pleural effusion and metastases containing 
cells which are already different from the original tumour and thus, more or less 
representative of this tumour. Indeed, the ER/PgR status sometimes differs between the 
metastasis and the original tumour from the same patient. Based on these observations, 
several teams have worked on the development of cell lines derived from a primary 
tumour (Amadori et al. 1993; Gazdar et al. 1998; Shen et al. 2009), which are much more 
representative of the in vivo cancerous tissues that lines derived from metastases, but 
which suffer from the same problems related to their relative homogeneity and instability 
in a long term use. Moreover, the establishment of cell lines from primary tumours 
remains a difficult achievement, failures mainly being the result of contamination by the 
stroma surrounding the tumour. 
- Confusion with some cell lines 
Besides these previous drawbacks, many criticisms have been made against BCCL because 
some of them have been proven not being from breast cancer origin. Indeed, some lines 
were contaminated by other cell types during their first years of use, then spread to other 
laboratories, and used on a large scale without further verifications of their true origin. 
Several cell lines were denounced as false, whereas it was not the case (Fogh et al. 1977; 
Nelson-Rees & Flandermeyer 1977). These contaminations have been subjects of 
controversial for a long time. However, studies have shown with certitude that two cell lines 
were not from their supposed origin.  
The MCF-7-ADRr cell line was developed in 1986 by Batist. It is derived from the lineage of 
human mammary adenocarcinoma MCF-7 and was rendered resistant to adriamycin 
treatment after exposition to increased concentrations of this drug. The obtained resistant 
cell line was also resistant to other agents such as actinomycin D, vinblastine and vincristine. 
However in 1998, the lineage between MCF-7 and MCF-7-ADRr became controversial, as 
shown by DNA fingerprinting studies and genetic comparison, so that the true origin of the 
cell line was undetermined and the cell line was renamed NCI/ADR-RES. Liscovitch and 
Ravid, in 2007, have collected data showing that NCI/ADR-RES were carcinoma ovarian 
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cells (Liscovitch & Ravid 2007), and experiments of Affymetrix SNP array analysis at the 
Sanger Institute (Cancer Genome Project) and of karyotyping, helped to put in evidence an 
indisputable resemblance of NCI/ADR-RES with the OVCAR-8 human ovarian carcinoma 
cell line. The most likely scenario is that the stock of MCF-7 cells from the National Cancer 
Institute used in 1986 for the development of the lineage, was contaminated with OVCAR-8 
cells before the first generation of MCF-7-ADR-r. OVCAR-8 cells are naturally resistant to 
adriamycin, and the in vitro selection probably eliminated the MCF-7 cells and allowed the 
survival of OVCAR-8 cells (Liscovitch & Ravid 2007). It can be noted that MCF-7-ADRr are 
no longer distributed by the international cell bank ATCC. 
The second misidentification concerns the MDA-MB-435 cell line established by Cailleau 
and colleagues in 1978. This cell line has been controversial in 2000, further to the results of 
DNA microarray analysis which suggested that these cells might be of melanocyte origin 
(Ross & Perou 2001). Some other results, obtained by microsatellite comparison analysis, 
karyotyping and comparative genomic hybridisation experiments (Rae et al. 2007), 
confirmed that MDA-MB-435 cells are in fact M14 melanoma cells.  
However, these two cell lines, MCF-7-ADRr and MDA-MB-235, are still used as breast 
cancer cell lines for some studies and are used for publications in international journals, 
while it has been proven that they are not from breast cancer origin (Lacroix 2008). The 
verification of the origin of a cell line is essential, and a way of ensuring that the cell lines 
are really from a well-defined origin is to make a short tandem repeat (STR) profiling. 
This method is used to confirm the identity of a cell line by comparison to a known profile 
and a periodic re-authentication of cell lines is advisable. Moreover, banks of cell lines 
such as ATCC guarantee the exact origin of their cells. Several authors suggested to prove 
the authenticity of the cell lines used for each publications (Burdall et al. 2003; Lacroix 
2008). 
2.1.3 Non cancerous immortalised cells as controls 
It should be noticed that the study of mammary tumours also involves the use of non 
cancerous cells which were immortalised. These cell lines were derived from healthy breast 
tissue, but only few models, obtained by different methods, are available.  
 The immortalisation could be the consequence of a particular composition of the 
growth medium. This is the case for the non-tumourigenic epithelial cell lines MCF-10A 
(adherent cells) and MCF-10F (floating cells) which were established from the same 
sample in the nineties (Soule et al. 1990). These cell lines were produced by a long-term 
culture in a special medium containing a low concentration of Ca2+ and no serum 
addition, which resulted in the apparition of immortalised cells with normal features of 
mammalian epithelial cells.  
 Two other cell lines were derived from a mammoplastic surgery. These cells named 
MCF-12A and MCF-12F became spontaneously immortal after unexpected exposition to 
high temperatures (45°C during 72 hours, Pauley et al. 1991).  
 Another cell line, hTERT-HME1 was obtained from the HME1 cells (Human 
Mammary Epithelial) which were immortalised by infection with the retrovirus 
pBabepuro+hTER. The immortality feature results from the exogenous expression of 
the telomerase gene coming from the viral infection (Van der Haegen & Shay 1993; 
Gollahon & Shay 1996).  
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 Under chemical pressure, normal cells in culture can also be immortalised. This is the 
case for some cell lines as 184A1 and 184B5 which were obtained by exposition to 
benzo[a]pyrène, a chemical carcinogen, leading to clonal events which are the origin of 
these immortal cell lines (Stampfer 1989).  
The use of these “non cancerous” cell lines is important to give a comparison point to results 
obtained with cancerous cell lines. However, there are drawbacks and controversy to their 
use, the major one concerning the way they were obtained. Indeed, if they are still non-
tumourigenic, they suffer of genetic modifications which lead them to become immortal. 
They are looking like normal cells, but they are not. 
2.1.4 Breast cell lines and metabolism of therapeutic drugs 
-  Drug metabolism 
The metabolic equipment of a cell can explain its sensitivity/resistance to drugs. Indeed, 
any xenobiotic molecule (therapeutic drugs included) undergoes the same metabolic fate in 
the cells. Briefly, enzymes of Phase I (essentially cytochromes P450 (CYP) dependent 
enzymes) ensure a bioactivation of the molecules while enzymes of Phase II conjugate the 
metabolites issued from Phase I to endogenous molecules (glucuronic acid, glutathione, 
sulfates…) in order to make them more water-soluble and to facilitate their elimination. 
Finally, transporters of Phase III are responsible for exporting these last products out of the 
cells. Each human organ is equipped with these enzymes, but their expression pattern 
differs quantitatively and qualitatively. The liver is the most efficient organ in metabolising 
processes, even if we know that some enzymes are more specifically expressed in non 
hepatic tissues. 
When considering the usefulness of breast cell lines as in vitro tools to predict sensitivity or 
resistance to a molecule, it is easy to perform, in first line, simple cytotoxicity tests. 
However, in order to explain the reasons of these cells behavior, or to predict the 
metabolism of a new compound, the knowledge of the metabolic equipment of the cells is 
necessary. As it is impossible, and not very interesting, to decline the results of the literature 
concerning breast cell lines and assays with the numerous chemical molecules which have 
been, precisely or not precisely, tested, we chose two examples of therapeutic drugs, used in 
breast cancer, that need to be bioactivated by CYP before exerting their deleterious effects in 
the cells: oxazaphosphorines and ellipticine. 
-  Metabolism of oxazaphosphorines 
The oxazaphosphorines generally used in pharmacology (i.e. cyclophosphamide (CPA), 
ifosfamide (IFO), and trofosfamide) represent an important group of chemotherapeutic 
agents. However, their use is limited by severe toxic side effects. New oxazaphosphorines 
derivatives have been developed in order to improve selectivity and to reduce toxicity but 
they won’t be studied here, due to their bioactivation process which is different from that of 
previous molecules (Zhang et al. 2005).  
Both CPA and IFO, the most widely used as alkylating agents, are prodrugs whose 
metabolism involves different cytochromes P450 (CYPs) catalysing 4-hydroxylations leading 
to acrolein and nitrogen mustards capable of reacting with DNA molecules leading to cell 
apoptosis and/or necrosis. Another pathway consists in an N-dealkylation whose last 
product is the toxic chloroacetaldehyde (Figure 1) (Rooseboom et al. 2004; Zhang et al. 2005). 
All these metabolites are highly reactive metabolites responsible for urotoxicity, 
neurotoxicity and nephrotoxicity. As all the mechanisms underlying these toxicities are not 
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elucidated, Mesna (Sodium 2-mercaptoethanesulfonate) is often used to limit these side 
effects (Giraud et al. 2010).  
 
 
 
 
Fig. 1. First phase of metabolism of the oxazaphosphorines by CYPs: hydroxylation leads 
to oxazaphosphorine mustards, and N-dealkylation results in chloracetaldehyde formation. 
From Rooseboom et al. 2004 with permission from ASPET. 
As already mentioned, several CYPs are involved in these drug metabolism: CYP2B6 
(Wang & Tompkins 2008; Mo et al. 2009; Bray et al. 2010), CYP3A4 (Kivisto et al. 1995), but 
also CYP2A6 (Di et al. 2009), CYP2C9, CYP2C19, CYP3A5 (Bray et al. 2010) and probably 
others. Figure 2 below, extracted from Wang & Tompkins 2008, shows the expression of 
the different human hepatic CYP and their contribution to metabolize clinically-used 
drugs. No analog study was performed in breast tissue, and a fortiori in breast cancer cell 
lines. However, the literature reports the presence of CYP3A4 (the CYP enzyme the most 
involved in drug metabolism) in MCF-7, T47D and MDA-MB-231 (Nagaoka et al. 2006; 
Chen et al. 2009; Mitra et al. 2011), of CYP2B6 in MCF-7 and T47D (Lo et al. 2010) whereas 
this information is not available for MDA-MB-231. While CYP2D6 and splicing variants 
similar to those found in breast cancer tissues were shown expressed in MCF-7 (Huang et 
al. 1997), no information about this CYP, to our knowledge, was related for T47D and 
MDA-MB-231. 
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Fig. 2. Hepatic CYP expression (A) and their contribution to metabolism of clinically-used 
drugs (B). From Wang & Tompkins 2008, permission granted by Bentham Science 
Publishers Ltd. 
- Metabolism of ellipticine 
Another example is given by ellipticine. This alkaloid compound found in several plants 
(Ochrosia, Aspidoserma subincanum, Bleekeria vitiensis) is a topoisomerase poison often 
used in ovarian and breast cancer treatment. It is also a prodrug whose efficiency depends 
on CYP activation. 13-hydroxy- and 12-hydroxy-ellipticine, responsible for the formation of 
DNA adducts, are generated by CYP1A1/2, CYP3A4 and CYP2C9.  
 
 
Fig. 3. Main pathways of ellipticine metabolism. Reprinted from Stiborova et al. 2011, ©2011, 
with permission from Elsevier. 
Members of the CYP1 family are usually expressed in extrahepatic tissues and it is not 
strange to find CYP1A1 in MCF-7 (Androutsopoulos et al. 2009; Stiborova et al. 2011), in 
MDA-MB-231 and T47D (Macpherson & Matthews 2010). We already mentioned the 
presence of CYP3A4 in the three cell lines, but no precise information is available for 
CYP2C9. 
This slight overview shows that the three main breast cancer cell lines are able to give 
interesting information about drugs that have to be bioactivated before exerting their 
deleterious effects in cancer cells. However, we must keep in mind that polymorphic 
variants of the genes coding these enzymes, or splicing variants, may influence the 
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pharmacology of any drugs. Very few information about that are available in patients, but 
no study was performed in breast cancer cells. 
BCCL have been created to study tumour development and related mechanisms and to test 
molecules potentially active. They are inevitable models for many studies. However, their 
extensive use in all areas of research on breast cancer remains sometimes controversial due 
to the over simplicity of the model, the instability of the strain, the existence of “false cell 
lines” and the failures of representativeness of the tumour. Thus, it clearly appears that 
these models are not sufficient to answer all the questions on breast cancer, and it is 
essential to turn to complementary models. Consequently, new models were introduced in 
the late 70s. They were used to a lesser extent than cell lines for a long time, but they tend to 
be more used now.  
2.2 Improving representativeness of the model: Direct culture of tumour fragment 
There are several methods to circumvent the problem of representativeness of BCCL, e.g. 
the direct culture of tumour fragments. The first attempts in this direction were made in the 
late 60s from tumours of 1mm3 volume (Matoska & Stricker 1967). However, these cultures 
were proven difficult due to the high thickness of the samples, preventing the diffusion of 
nutrients and oxygen to the center of the sample, and thus, avoiding a long-term cultivation 
in vitro. This method has been modified over time, and with the use of microtome, problems 
associated with diffusion of nutrients have been resolved. The samples are now constituted 
of extremely thin slices of about 150 to 200 µM thick (Nissen et al. 1983). 
This type of model was used to study the different inter-tumoural cell interactions and also 
to test the sensitivity to drugs (Milani et al. 2010). The slice tumour model associated with 
the development of microscopic analysis methods, such as the triple-fluorescence viability 
assay developed by Van Der Kuip, allowed the study of the cytotoxic effect of Taxol on this 
breast cancer model (Van Der Kuip et al. 2006).  
Another example of drug study is the evaluation of the action of cytokines and cytotoxic 
drugs on animal (MMTV-Neu mice) breast cancer slices, especially the monitoring of 
apoptosis increase and DNA damage after treatment with interferon-gamma or doxorubicin 
(Parajuli & Doppler 2009).  
The last noticeable example is the use of a tropism-modified oncolytic adenovirus, and a 
wild-type adenovirus on these slices to treat breast cancer. The results showed that the 
modified oncolytic adenovirus can infect and replicate in breast cancer tissue slices, 
suggesting the great potential of this model for evaluating the potential of oncolytic 
adenovirus constructs (Pennington et al. 2010).  
This list is not exhaustive and the literature shows that a lot of results were obtained by the 
slice culturing method, more particularly on the study of drugs effects like tamoxifen or 
paclitaxel (Conde et al. 2008; Sonnenberg et al. 2008; Rajendran et al. 2011).  
Although used since the late 70's, the slice technique evolved over time and was adapted to 
technological innovations. We may especially underline the use of silicon sensor chips 
wearing electrodes and sensors as a carrier of culture slice. The samples are deposited on the 
chip and data concerning the tumour-slice are analysed continuously during its cultivation 
and during its contact with drugs; measurements are made in real-time by the readout of 
ionic-sensitive field effect transistors and an oxygen electrode. This model was used to study 
the effects of Taxol on 200 slices of breast cancer, which revealed a dose-dependent decrease 
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of the metabolic activity showed by the measurement of a decrease in the acidification of the 
medium (Mestres et al. 2006). 
This technique has advantages and drawbacks. The direct culture of tumour fragment has 
the major advantage of preserving tissue architecture and all the cell populations 
constituting the human tumour. This method is thus a valuable technique which permits to 
take into account the whole tumour environment in vivo, allowing the investigation of the 
role of 3-dimensional structures and stromal interactions in tumour. It also allows to study 
the response of a particular tumour type to environmental stimulations, drugs, and 
cytokines under well-defined and reproducible conditions. 
However, the culture of tumour samples presents limitations that do not allow its 
widespread use. Obtaining tumour samples is submitted to ethical constraints relative to the 
use of patient samples for research. In addition, it must be performed under ideal 
conditions. Thus, the samples have to be prepared very quickly after their excision, which 
means that the research laboratory should have particular facilities to have a direct access to 
fresh tissues. Moreover, the samples excised by the surgeon are becoming smaller and 
smaller, due to early diagnoses, and the major part of the samples is kept for diagnosis. 
Then, if some sample is still available for research, priority is given to research on 
biomarkers of the tumour in order to give personalised therapies, and, only after, it is 
disposable for fundamental research. Additionally to the availability restrictions, the same 
sample cannot be used for many tests because of the limitations of growth of this tissue in 
vitro. Repetition of assays and comparative measurements are thus more difficult with this 
model. 
The use of samples from animal models with mammary tumour partially resolves the 
problem of availability of samples, but it also raises questions on the representativeness of 
the samples with human breast tumours. High improvements for providing human tissues 
of good quality will be brought by the emergence of biobanks. 
2.3 Circumventing the lack of diversity: Co-culturing of cell lines 
The co-culturing represents another way to circumvent the lack of cell diversity found in cell 
lines and to allow understanding of the tumoural proliferation mechanisms and inter-
cellular interactions within a tumour. It is an indispensable tool to elucidate the regulation 
of the tumour by epithelial and stromal components surrounding it.  
This model can be used by different ways: co-culturing of two cell types with a direct 
contact or co-culturing with a separating porous membrane between both cell types. The 
first method implicates to be able to differentiate the two cell types by microscopy. For that 
the use of fluorescent markers is a valuable tool (see Figure 4 for an example of co-culture of 
MDA-MB-231 with hASCs (adipose stem cells) respectively stained by the lipophilic tracers 
DiI (dialkylindocarbocyanines) and DiO (dialkyloxacarbocyanines), Pinilla et al. 2009).  
The second method allows a relative isolation of the two cell types, the porosity of the 
membrane separating them allowing the exchange of substances. The two techniques give 
complementary information on the behavior of cells studied, especially the crucial role of 
the inter-cellular communication (Cappelletti et al. 1991). 
In example, we could cite the co-culture of MDA-MB-231 and MCF-7, which has highlighted 
the importance of the heterogeneity of tumours for their growth and the role of oestrogen 
receptors. In this study, the co-culture of MCF-7 and MDA-MB-231 (respectively ER+ and 
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ER-) in a membrane separation system, was characterised by an increase of the MCF-7 cells 
growth rate in comparison with monocultures. This suggests that complex interactions 
between heterogenous cells population in tumour could explain the variability in tumour 
progression between different patients and the failure in response to endocrine treatment 
for some patients with ER+ tumours. 
 
 
Fig. 4. Human stem cells derived from adipose tissue (hASCs) and breast cancer cells (MDA-
MB-231) cultured in a monolayer co-culture system. (a) Direct microscopic observation of 
the co-culture of MDA-MB-231 and hASCs cells. (b) Overlay of DiO (hASCs), DiI (MDA-
MB-231) and DAPI (nucleus) stainings. (c) DiO staining of hASCs derived stem cells (green). 
(d) DiI staining of MDA-MB-231 breast cancer cells (red). Reprinted from Pinilla et al. 2009, 
©2009, with permission from Elsevier. 
Another example concerns the direct co-culturing of MCF-10A, a non-cancerous breast 
cell line, with the cancerous one MCF-7. An exposure to hormonal treatment with 17ǃ-
estradiol was able to inhibit the proliferation of MCF-7 cells in this co-culture, whereas 
this phenomenon was not observed in a monoculture of MCF-7. This highlighted the 
complex interactions between ER+ MCF-7 and ER- MCF-10A cells which may reflect 
physiologically relevant mechanisms of the paracrine regulation of cell proliferation 
(Spink et al. 2006).  
The co-culture of MCF-7 with fibroblasts derived from normal biopsies or from cancer 
biopsies also allowed to highlight the crucial role of fibroblasts in breast tumours. The 
results of two studies, one in direct co-culturing (Samoszuk et al. 2005) the second in 
membrane separated system (Dong-Le Bourhis et al. 1997), showed that MCF-7 growth rate 
was inhibited by fibroblasts issued from non cancerous tissues, but not by fibroblasts issued 
from tumourous tissues or serum-activated fibroblasts which enhanced MCF-7 growth rate. 
This suggests that fibroblasts could release some tumour growth inhibiting or activating 
factors. 
The role of tumour-associated macrophages in the proliferation of tumour cells was also 
studied by co-culturing macrophages with MCF-7 cells in a membrane separated system. This 
co-culture lead to a significant increase of MCF-7 invasiveness in vitro (Hagemann et al. 2004).  
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These repeatable techniques have permitted to highlight the regulation of mammary 
tumours by the surrounding stroma and the complex interactions between the cell subtypes 
of the tumour. 
2.4 A model with a tumour-like structure and cell diversity: 3-D culture 
Another particular model allows cells to grow in 3-dimensions, generally with a matrix 
support (Yuhas et al. 1978). This type of culture permits an in vitro depiction of tumour 
tissue more accurate than classical 2-dimensional cultures in monolayers, as this last model 
does not correctly imitate the architecture and cellular gradients of oxygen and nutrients 
that are found in poorly vascularised regions of the tumour. 
Only few cell lines are spontaneously able to establish spheroid architectures under certain 
culture conditions, but most of the systems require the use of synthetic or non-synthetic 
matrix. Systems are most often made of agar matrices or collagen support (Kim et al. 2004b). 
The Figure 5 show the growth of a MCF-7 spheroid growth in a hydrogel agarose matrix 
system (Fritsch et al. 2010). 
 
 
Fig. 5. Growth of a MCF-7 tumour spheroid in agarose hydrogel. The pictures represent the 
spheroid at 2 days old (a), 11 days old (b) and 27 days old (c) (the scale bar represent 50 μm). 
Reprinted by permission from Macmillan Publishers Ltd: Nature Physics, Fritsch et al. 2010, 
©2010. http://www.nature.com/nphys. 
Co-culturing of multiple cell types on these 3-dimensional systems is often used to study the 
relationship between cells, while simulating the tumour architecture with the most fidelity. 
These systems generally implicate the cultivation of tumour cells with other cell types like 
stromal, endothelial, fibroblasts and immune-competent cells. Moreover, this type of model, 
structurally like-looking the tumour, can be used quite indefinitely because it relies on the 
use of immortalised cells lines. This allows circumventing the problem of the lack of 
samples which is the major drawback of the tumour fragment culturing. 
More advanced systems have been derived from this principle; one can cite the microfluidic-
based 3-dimensional culturing (Bauer et al. 2010) that allows to grow multicellular tumour 
spheroid on a microchannel support, in order to analyze complex and heterotypic cellular 
interactions between breast cancer cells and fibroblast from the surrounding stroma. It has 
many advantages compared to the standard 3D culture: the culture volume and the number 
of needed cells are smaller than in standard support, the molecules are only distributed by 
diffusion mechanisms and the model is adapted to high throughput screenings. 
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2.5 Xenografts: An intermediary model between cell lines and in vivo models 
We previously saw that some in vitro models tend to provide essential information on the 
inter-cellular interactions, by taking more or less into account the 3-dimensional structure of 
the tumour, but none of them benefit from the nervous and hormonal regulations found in 
the living organism. 
There are particular models which can do perfectly the junction between in vitro and in vivo 
models, the xenografts. They are obtained by injecting cancer cells, usually derived from 
established cell lines, into a living organism. They are called xenografts because the injected 
cells are of human origin but are introduced into an animal organism, usually an 
immunodeficient rodent. The injection can be orthotopic (in breast gland) or heterotopic 
(localised in another part of the body, usually subcutaneously).  
The xenograft model has the advantage of using cells from human tumour cell lines for which 
a significant amount of data was collected in vitro, and to study their behavior in vivo. There 
are several models available for research on breast cancer, principally using immunodeficient 
mice. The model nude is by far the most commonly used (Kim et al. 2004a). It is characterised 
by an absence of a functional thymus and active T cells (Kindred 1971). The second common 
model is the SCID mouse (severe combined immunodeficiency). These mice have a deficit in 
VDJ recombinases that allow the binding of specific and non-specific parts of immunoglobulin 
and T cell receptor (Bosma & Carroll 1991). See Figure 6 illustrating the two common models 
of mice used for breast cancer xenografts: nude and SCID. 
 
A   B 
    
Fig. 6. Nude (A) and SCID (B) mice models xenografted respectively with MCF-7 and 
MDA-MB-231 breast cancer cell lines. (A) was taken from Nizamutdinova et al. 2008, by 
permission of Oxford University Press, and (B) was taken from Wang et al. 2010, with 
permission from ASBMB journals. 
The injected breast cancer cells mostly come from established cell lines like MCF-7, MDA-
MB-231, T-47-D or ZR-75-1. The first experiments of cell transplantations were made in the 
80s, and opened onto success in the establishment of malignant tumours in nude mice 
(Ozzello & Sordat 1980; Kim et al. 2004a). Since then, a lot of models have been developed 
for investigation of new treatments, therapeutic targets and establishment of new cancer 
detection method by medical imaging. 
This technique is widely used to test the effect of new antitumourous compounds or 
therapeutic methods, for example to test new virotherapies. Thus, a benign virus 
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Coxsackievirus 21 (CVA21) was intravenously injected in SCID mice xenografted with 
MDA-MB-231 breast cancer cells. CVA21 virus targets the receptors ICAM-1 and DAF that 
are overexpressed in breast cancer cells. In this experiment a rapid lysis focused on cancer 
cells was observed in all mice, making this virus a good candidate for use in systemic 
therapy (Skelding et al. 2009). See Figure 7 illustrating the effect of the virus on xenografted 
mice, visualised by bioluminescent analysis. 
 
  
Fig. 7. Observation of the oncolytic activity of CVA21 virus in SCID mouse xenografted 
with MDA-MB-231-luc. The breast cancer cells were xenografted into the mammary fat 
pad, mice were then treated with PBS or CVA21. Metastases were detected 3 weeks post-cell 
injection. The mice on the pictures are representative for bioluminescent observation at day 
42 post treatment. From Skelding et al. 2009, with kind permission from Springer Science 
and Business Media B.V. 
In the investigation of new treatments, the vitamin D3 receptors constitute good targets as they 
are present in over 80% of mammary tumours and they are negative growth regulator of both 
oestrogen-dependent and independent breast cancer cells in vitro. In a study published in 1998 
it was shown that EB1089, a vitamin D3 analog, was able to highly reduce the growth of 
tumour in nude mice xenografted with MCF-7 cells (tumours were 4-fold smaller than those in 
untreated mice). This reduction was resulting from an enhancement of apoptosis and reducing 
proliferation of tumour epithelial cells, suggesting the great potential of vitamin D3 analogs 
such as EB1089 against human breast cancer (VanWeelden et al. 1998). 
This model can also be used to explore new potential targets for anticancer therapies. A 
good example is the targeting of receptor ERǃ. In an experiment, standard T47D ERǂ+ ERǃ- 
and modified T47D ERǂ+ ERǃ+ (T47D stably transfected with a plasmid allowing the 
expression of the receptor ERǃ), were xenografted in SCID mice. 17ǃ-estradiol was then 
injected into mice. The treatment triggered an acceleration of tumour growth in mice 
xenografted with the native T47D strain, and conversely a regression of tumours T47D 
ERǃ+. These results emphasize the antagonistic role of ER receptors that appear to play an 
antitumourigenic role, and offered prospects for the development of ER-selective inhibitors. 
(Hartman et al. 2006).  
The targets cited above are non exhaustive. Many other therapeutic targets are tested with 
xenografts models, as it is the case of the VEGF pathway implicated in tumour angiogenesis 
(Le et al. 2008), or of cell cycle regulating proteins such as CDK kinases (Fry et al. 2004).  
The use of established cell lines for producing xenografts raises several questions about their 
relevance. The murine model presents considerable differences with the human body, 
concerning the biochemical and physiological regulation. Moreover, the stroma that will 
grow surround the tumour will be of murine origin and it will result in a chimeric tumour 
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which biology may significantly differ from human one (Kim et al. 2004a). Furthermore, in 
humans, the immune system plays an important role in the fight against tumour, whereas in 
xenografts models the immune system is totally absent.  
The xenograft model has some limitations but is the most accomplished of all models 
because it takes into account the complexity of the organism.  
Besides the xenografts, there are also murine models which can develop tumours 
spontaneously or under the influence of inducing compounds (Russo & Russo 1996). 
Although the achievement of these models is easy, their use is largely debated because of 
their relevance to the clinical situation. Indeed, murine breast cancers are most often caused 
by viral infections and are not hormone dependent, whereas a considerable proportion of 
human cancers are oestrogen dependent. To date there is no evidence suggesting a viral 
induction of breast cancer in humans. The biology of spontaneous rodent tumours differs 
from the human ones. The size, the oncogenic targets or the degree of maturation and 
differentiation of cells differ between the two species, making them hardly comparable.  
3. Conclusion 
In this chapter, we described the main models used in breast cancer research in order to 
obtain results of high scientific quality. In summary, we can say that BCCL models allow 
repeatable experiments with simple material and methods. They are inevitable models for 
basic studies and mechanistic explorations, but their use is still controversial owing to their 
approximate representativeness of breast tumours in human and to the existence of 
misidentified cell lines.  
Cultures of cancerous tissues preserve the tumour architecture and the cell diversity of a 
tumour but this model suffers of limited reproducibility and cannot be easily maintained for 
a long time. Co-culture systems offer an alternative with reproducible long term culture 
systems, and offer the possibility to study the relations between different types of cells in 
tumour, but this model suffers from the same controversies as BCCL as it mainly relies on 
their use. 
3-dimensional systems allow the mimicking of the tumour architecture and 
microenvironment, but very few cell lines are able to form spheroids under specific 
conditions.  
Considering the advantages and drawbacks of these models, the xenografts appear to be 
good alternative models as they enable to take into account the tumour structure, its 
microenvironment, the role of the metabolism and they preserve the cell diversity of the 
tumour. But as other models, they also have drawbacks principally due to the metabolic and 
physiological differences existing between human and rodents, and to the fact that the role 
of the immune system against tumour is not taken into account with the immunodeficient 
rodent models used for xenografts. 
Application of the 3Rs principle leaded to the development of all these models, but we 
showed that none of them is sufficient by itself and able to perfectly mimic breast cancer in 
human. However it clearly appears that all these models are essential to accumulate data 
and information to fight breast cancer. 
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